These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6436886)

  • 21. Dose-response effects of beta-phenylethylamine on stereotyped behavior in pargyline-pretreated rats.
    Moja EA; Stoff DM; Gillin JC; Wyatt RJ
    Biol Psychiatry; 1976 Dec; 11(6):731-42. PubMed ID: 1033771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of monoamine oxidase inhibitors and dopamine agonists on the behavior of mammal- and frog-eating snakes.
    Temple JG; Barthalmus GT
    Physiol Behav; 1994 May; 55(5):927-33. PubMed ID: 7912837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.
    Fozard JR; Zreika M; Robin M; Palfreyman MG
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):186-93. PubMed ID: 3937059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.
    Kitaichi Y; Inoue T; Nakagawa S; Boku S; Izumi T; Koyama T
    Eur J Pharmacol; 2010 Jul; 637(1-3):77-82. PubMed ID: 20406628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inhibition of A and B forms of MAO in the production of a characteristic behabioural syndrome in rats after 1-tryptophan loading.
    Squires RF; Lassen JB
    Psychopharmacologia; 1975; 41(2):145-51. PubMed ID: 1171489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: A source of some anomalies?
    Lewinsohn R; Glover V; Sandler M
    Biochem Pharmacol; 1980 Mar; 29(5):777-81. PubMed ID: 20227955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N,N-dipropargyl-2-phenylethylamine, a potential prodrug of 2-phenylethylamine: neurochemical and neuropharmacological studies in rat.
    Rao TS; Baker GB; Coutts RT
    Brain Res Bull; 1987 Jul; 19(1):47-55. PubMed ID: 3651840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor.
    Matsumoto J; Takahashi T; Agata M; Toyofuku H; Sasada N
    Jpn J Pharmacol; 1994 May; 65(1):51-7. PubMed ID: 8089930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unusual pattern of beta-phenylethylamine deamination in the rat heart.
    Tiago Guimarães J; Soares-da-Silva P
    Neurobiology (Bp); 2000; 8(1):109-18. PubMed ID: 11008882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioactive N,N-dimethylphenylethylamine: a selective radiotracer for in vivo measurement of monoamine oxidase-B activity in the brain.
    Inoue O; Tominaga T; Yamasaki T; Kinemuchi H
    J Neurochem; 1985 Jan; 44(1):210-6. PubMed ID: 3917289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAO-B inhibitor deprenyl and beta-phenylethylamine potentiate [D-ALA2]-Met-enkephalinamide-induced seizures.
    Ukponmwan OE; van der Poel-Heisterkamp AL; Haffmans J; Dzoljic M
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Feb; 322(1):38-41. PubMed ID: 6405286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of the inhibitory effect of phenylethylamine on spontaneous motor activity in mice by CPP-(+/-)-3-(2-carboxypiperazin-4-YL)-propyl-1-phosphonic acid.
    Lapin IP; Yuwiler A
    Pharmacol Biochem Behav; 1997 Feb; 56(2):199-204. PubMed ID: 9050075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on beta-phenylethylamine deamination by human placental monoamine oxidase.
    Oguchi K; Kobayashi S; Uesato T; Kamijo K
    Jpn J Pharmacol; 1981 Feb; 31(1):7-14. PubMed ID: 6788990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW; Hemrick-Luecke SK; Perry KW
    J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP; Galva MD; Villa F; Sciaba L; Picotti GB
    Biochem Pharmacol; 1995 Jun; 50(1):97-102. PubMed ID: 7605351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alteration of dopamine synthesis in rat striatum subsequent to selective type A monoamine oxidase inhibition.
    Schoepp DD; Azzaro AJ
    J Neurochem; 1981 Aug; 37(2):527-30. PubMed ID: 6790675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects.
    Turkish S; Yu PH; Greenshaw AJ
    J Neural Transm; 1988; 74(3):141-8. PubMed ID: 3145323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Properties of monoamine oxidase in monkey heart.
    Katayama M; Kobayashi S; Oguchi K; Yasuhara H
    Jpn J Pharmacol; 1984 Aug; 35(4):425-31. PubMed ID: 6438377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological and clinical implications of MAO-B inhibitors.
    Yu PH
    Gen Pharmacol; 1994 Dec; 25(8):1527-39. PubMed ID: 7721026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.